Exacerbator subtypes in the TIOtropium Safety and Performance In Respimat (TIOSPIR™) trial
Article 2015 en
Authors
CG
Christian Geßner
PC
Peter M. Calverley
DD
Daniel Dusser
Abstract
1 min read
Background: Cardiovascular (CV) comorbidities in chronic obstructive pulmonary disease (COPD) patients are frequent. We evaluated whether baseline variables can predict mortality and CV events in the TIOSPIR trial (17,116 COPD patients receiving tiotropium Respimat 5 or 2.5µg or HandiHaler 18µg for a mean of 2.3 yrs).
Leanne Mooney, Pardeep S. Jhund, Inder S. Anand, Akshay S. Desai, Aldo Maggioni, Jean L. Rouleau, Karl Swedberg, Dirk J. van Veldhuisen, Michael R. Zile, Scott D. Solomon, John J.V. McMurray
Leanne Mooney, Nathaniel M. Hawkins, Pardeep S. Jhund, Margaret M. Redfield, Muthiah Vaduganathan, Akshay S. Desai, Jean L. Rouleau, Masatoshi Minamisawa, Amil M. Shah, Martin Lefkowitz, Michael R. Zile, Dirk J. van Veldhuisen, Marc A. Pfeffer, Inder S. Anand, Aldo Maggioni, Michele Senni, Brian Claggett, Scott D. Solomon, John J.V. McMurray
Discussion(0)
No comments yet. Be the first to comment.